Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade

Heart Rhythm. 2016 Feb;13(2):609-13. doi: 10.1016/j.hrthm.2015.09.027. Epub 2015 Sep 28.
No abstract available

Keywords: Arrhythmia; Catecholaminergic polymorphic ventricular tachycardia; Flecainide; Side effects; Treatment; β-blockers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists* / administration & dosage
  • Adrenergic beta-Antagonists* / adverse effects
  • Adult
  • Anti-Arrhythmia Agents / administration & dosage
  • Anti-Arrhythmia Agents / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Drug Substitution / methods
  • Drug Tolerance
  • Electrocardiography / methods
  • Flecainide* / administration & dosage
  • Flecainide* / adverse effects
  • Humans
  • Medication Therapy Management
  • Patient Selection
  • Tachycardia, Ventricular / diagnosis
  • Tachycardia, Ventricular / drug therapy*
  • Tachycardia, Ventricular / physiopathology
  • Treatment Outcome
  • Voltage-Gated Sodium Channel Blockers / administration & dosage
  • Voltage-Gated Sodium Channel Blockers / adverse effects

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Voltage-Gated Sodium Channel Blockers
  • Flecainide

Supplementary concepts

  • Polymorphic catecholergic ventricular tachycardia